Pulmovant, a unit of Roivant Sciences Ltd. (ROIV), Thursday said its drug candidate mosliciguat for the treatment of Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD), has been granted orphan drug designation by Japan's Ministry of Health, Labour and Welfare (MHLW).
A Phase 2 study of mosliciguat in PH-ILD, dubbed PHocus is underway.
Orphan drug designation from MHLW provides key regulatory and development benefits, including priority consultation, reduced regulatory fees, and up to 10 years of market exclusivity following potential approval.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.